News Hub | News Direct

All Industries

Article thumbnail News Release

Top 4 Cannabis Stocks to Watch Ahead of Potential Federal Policy Changes


When it comes to investing in the legal marijuana industry, they don't call it the "green rush" for nothing. Many analysts are projecting massive growth for the cannabis industry. New Frontier, a Washington D.C.-based cannabis research firm, expects total U.S. legal cannabis sales to exceed $57 billion by 2030. In light of such tremendous growth potential, many see marijuana as a golden investment opportunity. Cannabis is now legal in 37 states for medical use and fully legal in 23 states. However, on a federal level, its status has barely changed since the 1970s, sharing the same classification as heroin, ecstasy, and LSD. Cannabis stocks jumped after the U.S. Department of Health and Human Services recommended easing restrictions on marijuana in August. With that date approaching, let's take a look at a few stocks in the sector for your radar. KindlyMD, Inc. (NASDAQ: KDLY) is a healthcare company focused on integrating traditional primary care and pain management with behavioral and alternative therapies to combat opioid dependency in the U.S. As Utah's largest alternative pain treatment center, KindlyMD prioritizes holistic pain management and often recommends medical cannabis to improve patient health outcomes. In response to the ongoing opioid crisis, which saw over 80,000 opioid-related deaths in 2021, KindlyMD offers comprehensive care plans to ensure the safe use of opioids when necessary, including appropriate dosing and weaning plans. The company also educates patients on medical cannabis as an alternative treatment option, having conducted over 60,000 patient visits to date. Last month, KindlyMD successfully completed its initial public offering, raising approximately $6.8 million. This milestone demonstrates strong investor confidence in the company's comprehensive approach to healthcare. KDLY announced in June that it had become the first alternative medical treatment company in Utah to sign contracts with the state's top insurance payors, including Select Health, Medicare, and Medicaid. This credentialing allows nearly 70% of Utah's population to access KindlyMD's services through their insurance plans. Tim Pickett, PA-C, founder and CEO, stated, "This is a major milestone for KindlyMD. Now, the scope of services we provide at our Company-branded clinics, including behavioral healthcare and medical interventions incorporating alternative medicine, are covered by and reimbursable by the largest insurance providers across the state." On June 10, KDLY announced a collaboration with Curaleaf Holdings, Inc., (OTCQX: CURLF) to expand patient education on medical cannabis in Utah. This partnership includes community care events throughout the summer, aiming to enhance patient understanding of holistic pain management. Pickett noted, "Our collaboration with Curaleaf will provide more patients with access to pain management treatment options and alternative therapies, including medical cannabis care in the state of Utah." Additionally, KindlyMD further strengthened its position by contracting with Blue Cross Blue Shield, increasing its statewide insurance coverage to nearly 80%. Pickett commented, "The addition of Blue Cross Blue Shield under Utah's leading insurance payors reflects our commitment to transforming healthcare and making a meaningful difference in people's lives." As the cannabis industry continues to gain momentum, KDLY stands out for its unique approach to integrating medical cannabis into comprehensive pain management and behavioral health plans. This strong foundation, coupled with the company’s expanding insurance coverage and successful partnerships, positions KindlyMD for potential growth. For investors looking to tap into the burgeoning cannabis market, KDLY presents a compelling opportunity. Tilray Brands, Inc. (NASDAQ: TLRY) is a global leader in medical cannabis, dedicated to improving patient lives through a diverse portfolio of brands including Tilray, Aphria, Broken Coast, Symbios, and Navcora. From its origins as a licensed producer in Canada, Tilray has expanded its operations to Europe, establishing GMP-certified production facilities in Portugal and Germany. Today, Tilray Medical is a major supplier of medical cannabis across 20 countries and five continents, serving patients, healthcare professionals, and governments. Recently, Tilray announced it will release its financial results for the fourth quarter and full fiscal year ended May 31, 2024, on July 29, 2024, at market close. Despite recent fluctuations in share price, Tilray remains a formidable player in the cannabis industry, demonstrating long-term strength through its expanding craft beer business. Acquiring brands from Anheuser-Busch in 2023, Tilray has doubled its alcohol sales, diversifying its revenue streams and enhancing its position in a competitive market. TLRY’s strategic investments include building a $250 million cash reserve to support future acquisitions and operational expansion. This move, while diluting shares, positions Tilray advantageously for growth in the evolving cannabis sector. The company holds the top market share in Canada and Germany and distributes medical cannabis globally. In its Q3 2024 report, TLRY reported revenue of $188.3 million, a 30% increase from the previous year, although it fell short of the $198.3 million analysts' expectations. The company significantly reduced its loss to $82.1 million from $1.2 billion a year ago. With notable hedge fund interest and a robust portfolio, TLRY is well-positioned to benefit from potential federal legalization of medical cannabis in the U.S. Irwin Simon, CEO, highlighted Tilray's readiness to capitalize on regulatory changes, particularly the potential rescheduling of cannabis to Schedule III, which would facilitate the sale of pharmaceutical-grade products in the U.S. Canopy Growth Corporation (NASDAQ: CGC) is a global leader in the cannabis industry, committed to enhancing lives through innovative products and a diverse brand portfolio. With notable brands like Doja, 7ACRES, Tweed, and Deep Space, as well as vaporizer technology from Storz & Bickel, Canopy Growth stands out for its dedication to premium and mainstream cannabis products. The company recently reported its financial results for the fourth quarter and fiscal year ended March 31, 2024. For Q4 FY2024, Canopy Growth achieved a 7% increase in net revenue year-over-year, or 16% excluding divested businesses. This growth was significantly driven by a 43% revenue increase from Storz & Bickel, reflecting strong sales of the new Venty portable vaporizer. The Canadian cannabis sector saw a 16% rise in medical cannabis revenue, contributing to a 4% increase in overall Canadian cannabis revenue. In fiscal year 2024, Canopy Growth made impressive strides in reducing costs. The total cost of goods sold (COGS) decreased by 45%, with Canadian cannabis COGS dropping 54% year-over-year. Consolidated gross margins improved to 27%, marking a significant 4,600 basis point increase from the previous year. Despite an operating loss of $229 million and an adjusted EBITDA loss of $59 million, Canopy Growth showed a 72% improvement in adjusted EBITDA loss compared to FY2023. The company's financial stability is also notable, with $203 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Strengthening balance sheet actions have positioned Canopy with no material debt obligations until March 2026. David Klein, CEO of Canopy Growth, highlighted the company’s strong foundation for future growth, emphasizing its momentum in the global cannabis markets and its readiness to capitalize on regulatory advancements in Germany and the U.S. As Canopy Growth enters FY2025, its broad portfolio of impactful brands and expanding U.S. ecosystem set the stage for continued success. Aurora Cannabis Inc. (NASDAQ: ACB), headquartered in Edmonton, Alberta, is a leading global player in the cannabis industry, serving medical and recreational markets across Canada, Europe, Australia, and South America. The company has built a diverse portfolio of cannabis brands, including Aurora Drift, San Rafael '71, Daily Special, Tasty's, and Greybeard for adult use, and MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. for medical purposes. Additionally, Aurora's international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. Aurora's strategic focus on innovation and high-quality products has positioned it as a significant force in the global cannabis market. The company recently reported its financial results for the fiscal year 2024, highlighting substantial improvements and operational efficiency. For Q4 2024, Aurora Cannabis achieved a 5% year-over-year increase in total net revenue, reaching $67.4 million. The global medical cannabis sector drove this growth, with net revenue rising 20% to $45.6 million. The company's strong performance in medical cannabis was bolstered by the acquisition of MedReleaf Australia and increased sales in Poland and the UK. Aurora's record annual adjusted EBITDA of $12.8 million marks its sixth consecutive quarter of positive adjusted EBITDA, reflecting the company's effective cost management and revenue growth. Aurora ended the fiscal year with approximately $180 million in cash and is debt-free in its cannabis business. The company remains focused on achieving positive free cash flow by the end of 2024. According to CEO Miguel Martin, Aurora's leadership in the global medical cannabis market is distinguished by its ability to meet diverse patient needs worldwide, underscored by a significant increase in its quarterly adjusted gross margin to 66%. With a solid financial foundation and a robust global presence, Aurora Cannabis is well-positioned for continued growth and success in the evolving cannabis industry. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of content related to KDLY. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details Mark McKelvie +1 585-301-7700 Company Website

July 22, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

BestGrowthStocks.Com Issues Analysis on the Next Beneficiaries of the AI Revolution

SoundHound AI Inc.

NEW YORK, NY / NewsDirect / July 22nd, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of SoundHound AI, Inc. a pioneer in advanced voice-enabled AI and conversational intelligence technologies and a comprehensive analysis of the next beneficiaries of the AI revolution. SoundHound AI, Inc. (NASDAQ: SOUN) has garnered significant investor attention following multiple recent announcements that could prove to be significant catalysts for the AI company. Best Growth Stock's full report offers an analysis of SoundHound’s operations, potential upcoming catalysts, growth drivers, financials, share structure, chart, and more. Bonus content “The Next Beneficiaries of the AI Revolution” offers a comprehensive analysis of the next beneficiaries of the AI revolution, which ones stand to benefit near term, and stocks under $15/share to watch within each sector. Access this full analysis and bonus AI report with no obligation: Access this full analysis and bonus AI report with no obligation: About SoundHound AI SoundHound AI (Nasdaq: SOUN), a global leader in conversational intelligence, offers voice AI solutions that let businesses offer incredible conversational experiences to their customers. Built on proprietary technology, SoundHound’s voice AI delivers best-in-class speed and accuracy in numerous languages to product creators across automotive, TV, and IoT, and to customer service industries via groundbreaking AI-driven products like Smart Answering, Smart Ordering, and Dynamic Drive Thru, an AI-powered multimodal food ordering solution. Along with SoundHound Chat AI, a powerful voice assistant with integrated Generative AI, SoundHound powers millions of products and services, and processes billions of interactions each year for world class businesses. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry SOURCE: BestGrowthStocks.Com Contact Details Media Source LLC Steve Macalbry +1 989-274-7778

July 22, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Benchmark International Successfully Facilitated the Transaction Between D.R. Price Engineering & Land Surveying, Inc and Boos Resource & Technology Group

Benchmark International

Benchmark International has successfully facilitated a transaction between Honaker, VA-based D.R. Price Engineering & Land Surveying, Inc. (“D.R. Price”) and Naperville, IL-based Boos Resource & Technology Group (“Boos”). D.R. Price is a multi-discipline engineering and surveying firm that provides a broad spectrum of structural engineering, civil engineering, mining engineering, land planning, land surveying, and construction surveying services. “D.R. Price President Richard Bostic grew a fantastic niche business serving the coal mining and other industries in Southwest Virginia and its environs,” commented Benchmark Senior Transaction Director William Sullivan. “The company adds a key piece to the Boos regional growth strategy and will contribute greatly to the acquirer’s capabilities and reach in the region. This transaction was a great fit from both an integration and a cultural standpoint, and we are proud to have supported our client throughout this process to a successful conclusion.” Founded in 1988, D.R. Price serves residential, commercial, and government customers throughout Virginia, West Virginia, and Kentucky. The company uses the latest industry technologies to perform its services, including GPS surveying, drone technology, electronic data collection, and AutoCAD mapping. D.R. Price has grown significantly in recent years, largely due to increasing customer referrals, a steady flow of new customers, and expanded project scopes. Boos Resource and Technology Group is an environmental and energy-focused solutions provider that delivers timely and cost-effective construction management, infrastructure, natural gas, and industrial services to clients across the United States and beyond. Europe: Michael Lawrie at +44 (0) 161 359 4400 / Americas: Sam Smoot at +1 (813) 898 2350 / Africa: Anthony McCardle at +27 21 300 2055 / ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 Company Website

July 22, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

The Financial Select Sector SPDR Fund (XLF): A Gateway to Financial Institutions

Select Sector SPDR

The Financial Select Sector SPDR Fund (XLF) offers investors a path to engage with the U.S. financial sector. Comprised of the S&P 500's financial stocks, XLF offers a diversified approach to investment in this dynamic segment of the economy. A Balanced Investment Opportunity XLF's strategy involves a modified market capitalization-weighted index, focusing on some of the most significant U.S. financial companies. This method aims to provide a balanced mix of stability from large-cap entities and potential growth opportunities across various financial sub-sectors including banking, credit services, capital markets, and insurance. Insight into XLF's Holdings* The fund's holdings are components of the S&P 500 and offer investors a comprehensive view of the financial landscape, featuring: Berkshire Hathaway B (12.94%): A conglomerate with diverse interests JP Morgan Chase (10.21%): A global financial services firm Visa A (7.26%): A leader in digital payments Mastercard A (6.36%): Renowned for payment processing solutions Bank of America Corp (4.75%): A multinational banking and financial services institution Wells Fargo (3.64%): Offering a wide range of financial services Goldman Sachs (2.56%): Specializes in investment banking and management S&P Global (2.51%): Known for its financial data and analytics American Express Co (2.31%): Providing payment card services globally Progressive Corp (2.14%): Recognized for its insurance products and services An Accessible Path to the Financial Sector The Financial Select Sector SPDR Fund ( XLF ) is designed to be an accessible option for those interested in the financial sector. It allows investors to potentially benefit from the sector’s dynamics without needing to select individual stocks. The fund's broad diversification and focus on significant financial institutions aim to offer a balanced exposure to the sector's potential. For More Information To learn more about how the Financial Select Sector SPDR Fund (XLF) operates and whether it fits into your investment strategy, we invite you to visit our website or reach out to our investor relations team. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 6/30/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: Website: *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007679 EXP 9/30/24 Contact Details Dan Dolan +1 203-935-8103 Company Website

July 22, 2024 05:00 AM Eastern Daylight Time

Article thumbnail News Release

OpenBet Scores Big with Euro 2024: Over 140 Million Bets Processed

AM Europe

OpenBet successfully processed over 140 million bets during the UEFA Euro 2024 tournament, demonstrating the scalability and reliability of its technology. The company facilitated a peak of £850 million wagered in a single month, highlighting the significant interest in the competition. England and Spain were the most popular bets throughout the knockout stages, reflecting the strong support for these traditional powerhouses. Additionally, Austria experienced a surge in bets following their surprising victory, showcasing the dynamic nature of the betting landscape. Overall, OpenBet's performance during Euro 2024 underscores its position as a leading provider of sports betting solutions. The company's ability to handle high volumes of bets while maintaining a secure and reliable experience for customers is a testament to its commitment to innovation and excellence. Contact Details Kimberly C. Addis +44 7766 676396

July 22, 2024 04:02 AM Eastern Daylight Time

Article thumbnail News Release

BDA Announces 2025 Bermuda Risk Summit Dates

Bermuda Business Development Agency

Hamilton, Bermuda, July 19 th 2024: The Bermuda Risk Summit is set to take place from March 10-12, 2025, at the Hamilton Princess & Beach Club. This premier event promises to bring together industry leaders and experts for three days of insightful discussions and networking opportunities. Kendaree Burgess, COO of the Bermuda Business Development Agency, remarked, " The 2025 Bermuda Risk Summit is a must attend event for Bermuda’s Risk sector, bringing together industry thought leadership, innovation and interest from those seeking to make Bermuda their domicile of choice. This event highlights Bermuda's leadership in risk management and offers a unique platform for industry experts to network and collaborate.” The 2024 Bermuda Risk Summit saw over 450 attendees, with 40% traveling from 30 different countries. The summit featured 50 industry-leading speakers, addressing crucial topics that shape the risk management landscape. Sponsorship Opportunities Sponsorship opportunities for the Bermuda Risk Summit 2025 are now available! Sponsors will have the chance to gain significant visibility and connect with influential leaders in the risk management sector. If you are interested in sponsorship, click here or email Early Bird Registration and Accommodation Members of the public are encouraged to register early. An early bird rate of $395 will be available until September 30. To avoid disappointment, click here to reserve your hotel room online or call 1-441-295-3000, or the Global Reservations Centre at 1-800-441-1414, using the booking code: ‘Bermuda Risk Summit’ to take advantage of our preferred rate. For more information, please visit our website or contact us at BERMUDA BUSINESS DEVELOPMENT AGENCY BDA.BM +1 441 292 0632 CONNECTING BUSINESS The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. The Bermuda Business Development Agency (BDA) encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Contact Details Bermuda’s Business Development Agency (BDA) Melvin Dickinson +1 441-707-0038 Company Website

July 19, 2024 01:56 PM Eastern Daylight Time

Article thumbnail News Release

Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share exciting news about a significant achievement for the company. Tonix Pharmaceuticals has been awarded a potential contract worth up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. This contract aims to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections, thereby enhancing the medical readiness of military personnel in biological threat environments. Dr. Lederman explained that Tonix’s program will concentrate on the optimization and development of its TNX-4200 program. The goal is to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families through extensive preclinical evaluation. The program is expected to establish essential physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug (IND) submission, ultimately funding a first-in-human Phase 1 clinical study. The agreement with DTRA is a strategic move to address the DoD’s objective of protecting U.S. Joint Forces from potential biological weapon threats. The DoD announced in December 2022 that it aims to move beyond the traditional ‘one bug, one drug’ approach and is seeking broad-spectrum drugs, as predicting which viruses or how many may be deployed in a biological threat scenario is challenging. Dr. Lederman emphasized that the collaboration with DTRA underscores Tonix Pharmaceuticals' commitment to advancing medical readiness and protection for military personnel. By developing a broad-spectrum antiviral agent, Tonix aims to provide a versatile and robust solution to potential viral threats, enhancing the preparedness and resilience of the U.S. military in diverse and unpredictable biological threat environments. The TNX-4200 program’s focus on creating an effective, orally available antiviral agent highlights Tonix’s innovative approach to addressing complex medical challenges. The successful development of this broad-spectrum antiviral could significantly impact the way viral infections are managed in military and potentially civilian populations, offering a proactive measure against a wide array of viral threats. Tonix Pharmaceuticals continues to be at the forefront of medical innovation, dedicated to developing cutting-edge solutions that meet the evolving needs of the healthcare and defense sectors. The support from the DoD through this substantial contract is a testament to the potential and importance of Tonix’s TNX-4200 program in safeguarding the health and readiness of military personnel against biological threats. Contact Details Proactive Investors +1 604-688-8158

July 19, 2024 12:48 PM Eastern Daylight Time

Article thumbnail News Release

Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test

Mainz Biomed N.V.

Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer screening product. This product incorporates a novel portfolio of mRNA biomarkers. Achieving this designation could potentially expedite the approval process, significantly benefiting early cancer detection efforts. Baechler emphasized that the regulatory submission is backed by consistently strong results from the company's clinical studies, ColoFuture and eAArly Detect, as well as data from a comprehensive pooled study encompassing both the European and U.S. cohorts, which were presented at ASCO 2024. These studies have culminated in the final configuration of the Next Generation Test. This test integrates the Fecal Immunochemical Test with proprietary mRNA biomarkers and is enhanced by an advanced AI and machine learning algorithm. This integrated approach is set to be employed in the FDA premarket approval study. The Next Generation Test configuration was rigorously evaluated in a clinical setting involving 295 subjects from 21 specialized gastroenterology centers across the United States. The results underscored the exceptional efficacy of Mainz Biomed’s multimodal screening test, which allows for precise differentiation among colorectal cancer, advanced adenomas, non-advanced adenomas, and samples with no pathological findings. The FDA’s Breakthrough Devices Designation program is designed to accelerate the development, assessment, and review of medical devices and combination products that provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. This designation for Mainz BioMed's colorectal cancer test could pave the way for quicker market access and wider availability of this critical diagnostic tool. Contact Details Proactive North America +1 604-688-8158

July 19, 2024 12:38 PM Eastern Daylight Time

Article thumbnail News Release

Immersive Engagement Is The Future – CEO Speaks About Company's Innovations That Keep Pushing What's Possible


By Johnny Rice, Benzinga Ann Hand, CEO of Super League Enterprise Inc (NASDAQ: SLE), was recently interviewed by Benzinga. Super League helps brands reach Gen Z and Gen Alpha in the 3D environments that they frequent. Platforms like Roblox (NYSE: RBLX), Fortnight and others represent significant opportunities to marketers as they allow for very interactive and immersive experiences. Ms. Hand spoke about the exciting developments her company has been making, such as SOUNDZ, its latest tool for driving real engagement and commerce. Learn more here: Featured photo by Vinicius "amnx" Amano on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 Company Website

July 19, 2024 09:00 AM Eastern Daylight Time

Video Image
12345 ... 3659